Phase I Study of Oral Cyclophosphamide and Oral Topotecan for Children with Recurrent or Refractory Solid Tumors

Daniel C. Bowers, Victor M. Aquino, Patrick J. Leavey, Robert O. Bash, Janna M. Journeycake, Gail Tomlinson, Arlynn F. Mulne, Heidi J. Haynes, Naomi J. Winick

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Background. To determine the maximum-tolerated duration and dose-limiting toxicity of a daily schedule of orally administered cyclophosphamide and topotecan in pediatric patients with recurrent or refractory malignant solid tumors. Methods. Patients received oral cyclophosphamide (50 mg/m 2/dose) in the morning followed by topotecan (0.8 mg/m 2/dose) 8-12 hr later for an escalating number of consecutive days (10, 14, and 17 days). Results. Seventeen pediatric patients were treated with oral cyclophosphamide and topotecan for durations of 10-17 days for a total of 58 treatment courses. Reversible hematologic toxicity (neutropenia and thrombocytopenia) was the dose-limiting toxicity. Nonhematologic toxicities of greater than grade 3 were not observed. A partial response (neuroblastoma following myeloablative chemotherapy and stem cell rescue) and prolonged stable disease (medulloblastoma) were each observed in one patient. Conclusions. The recommended duration of therapy with a daily schedule of both oral cyclophosphamide (50 mg/m2/day) and topotecan (0.8 mg/m 2/day) for previously treated pediatric patients with recurrent or refractory solid tumors is 14 consecutive days. The observed dose limiting toxicity (DLT) was reversible neutropenia. This regimen was well tolerated in heavily pretreated patients and demonstrated activity against recurrent pediatric solid tumors.

Original languageEnglish (US)
Pages (from-to)93-98
Number of pages6
JournalPediatric Blood and Cancer
Volume42
Issue number1
StatePublished - Jan 2004

Fingerprint

Topotecan
Cyclophosphamide
Pediatrics
Neoplasms
Neutropenia
Appointments and Schedules
Medulloblastoma
Maximum Tolerated Dose
Neuroblastoma
Thrombocytopenia
Stem Cells
Drug Therapy
Therapeutics

Keywords

  • Angiogenesis
  • Cyclophosphamide
  • Topotecan
  • Vascular targeting

ASJC Scopus subject areas

  • Cancer Research
  • Pediatrics, Perinatology, and Child Health
  • Hematology

Cite this

Phase I Study of Oral Cyclophosphamide and Oral Topotecan for Children with Recurrent or Refractory Solid Tumors. / Bowers, Daniel C.; Aquino, Victor M.; Leavey, Patrick J.; Bash, Robert O.; Journeycake, Janna M.; Tomlinson, Gail; Mulne, Arlynn F.; Haynes, Heidi J.; Winick, Naomi J.

In: Pediatric Blood and Cancer, Vol. 42, No. 1, 01.2004, p. 93-98.

Research output: Contribution to journalArticle

@article{82f4719d16f546ac8b1fa1c5b5beadd3,
title = "Phase I Study of Oral Cyclophosphamide and Oral Topotecan for Children with Recurrent or Refractory Solid Tumors",
abstract = "Background. To determine the maximum-tolerated duration and dose-limiting toxicity of a daily schedule of orally administered cyclophosphamide and topotecan in pediatric patients with recurrent or refractory malignant solid tumors. Methods. Patients received oral cyclophosphamide (50 mg/m 2/dose) in the morning followed by topotecan (0.8 mg/m 2/dose) 8-12 hr later for an escalating number of consecutive days (10, 14, and 17 days). Results. Seventeen pediatric patients were treated with oral cyclophosphamide and topotecan for durations of 10-17 days for a total of 58 treatment courses. Reversible hematologic toxicity (neutropenia and thrombocytopenia) was the dose-limiting toxicity. Nonhematologic toxicities of greater than grade 3 were not observed. A partial response (neuroblastoma following myeloablative chemotherapy and stem cell rescue) and prolonged stable disease (medulloblastoma) were each observed in one patient. Conclusions. The recommended duration of therapy with a daily schedule of both oral cyclophosphamide (50 mg/m2/day) and topotecan (0.8 mg/m 2/day) for previously treated pediatric patients with recurrent or refractory solid tumors is 14 consecutive days. The observed dose limiting toxicity (DLT) was reversible neutropenia. This regimen was well tolerated in heavily pretreated patients and demonstrated activity against recurrent pediatric solid tumors.",
keywords = "Angiogenesis, Cyclophosphamide, Topotecan, Vascular targeting",
author = "Bowers, {Daniel C.} and Aquino, {Victor M.} and Leavey, {Patrick J.} and Bash, {Robert O.} and Journeycake, {Janna M.} and Gail Tomlinson and Mulne, {Arlynn F.} and Haynes, {Heidi J.} and Winick, {Naomi J.}",
year = "2004",
month = "1",
language = "English (US)",
volume = "42",
pages = "93--98",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - Phase I Study of Oral Cyclophosphamide and Oral Topotecan for Children with Recurrent or Refractory Solid Tumors

AU - Bowers, Daniel C.

AU - Aquino, Victor M.

AU - Leavey, Patrick J.

AU - Bash, Robert O.

AU - Journeycake, Janna M.

AU - Tomlinson, Gail

AU - Mulne, Arlynn F.

AU - Haynes, Heidi J.

AU - Winick, Naomi J.

PY - 2004/1

Y1 - 2004/1

N2 - Background. To determine the maximum-tolerated duration and dose-limiting toxicity of a daily schedule of orally administered cyclophosphamide and topotecan in pediatric patients with recurrent or refractory malignant solid tumors. Methods. Patients received oral cyclophosphamide (50 mg/m 2/dose) in the morning followed by topotecan (0.8 mg/m 2/dose) 8-12 hr later for an escalating number of consecutive days (10, 14, and 17 days). Results. Seventeen pediatric patients were treated with oral cyclophosphamide and topotecan for durations of 10-17 days for a total of 58 treatment courses. Reversible hematologic toxicity (neutropenia and thrombocytopenia) was the dose-limiting toxicity. Nonhematologic toxicities of greater than grade 3 were not observed. A partial response (neuroblastoma following myeloablative chemotherapy and stem cell rescue) and prolonged stable disease (medulloblastoma) were each observed in one patient. Conclusions. The recommended duration of therapy with a daily schedule of both oral cyclophosphamide (50 mg/m2/day) and topotecan (0.8 mg/m 2/day) for previously treated pediatric patients with recurrent or refractory solid tumors is 14 consecutive days. The observed dose limiting toxicity (DLT) was reversible neutropenia. This regimen was well tolerated in heavily pretreated patients and demonstrated activity against recurrent pediatric solid tumors.

AB - Background. To determine the maximum-tolerated duration and dose-limiting toxicity of a daily schedule of orally administered cyclophosphamide and topotecan in pediatric patients with recurrent or refractory malignant solid tumors. Methods. Patients received oral cyclophosphamide (50 mg/m 2/dose) in the morning followed by topotecan (0.8 mg/m 2/dose) 8-12 hr later for an escalating number of consecutive days (10, 14, and 17 days). Results. Seventeen pediatric patients were treated with oral cyclophosphamide and topotecan for durations of 10-17 days for a total of 58 treatment courses. Reversible hematologic toxicity (neutropenia and thrombocytopenia) was the dose-limiting toxicity. Nonhematologic toxicities of greater than grade 3 were not observed. A partial response (neuroblastoma following myeloablative chemotherapy and stem cell rescue) and prolonged stable disease (medulloblastoma) were each observed in one patient. Conclusions. The recommended duration of therapy with a daily schedule of both oral cyclophosphamide (50 mg/m2/day) and topotecan (0.8 mg/m 2/day) for previously treated pediatric patients with recurrent or refractory solid tumors is 14 consecutive days. The observed dose limiting toxicity (DLT) was reversible neutropenia. This regimen was well tolerated in heavily pretreated patients and demonstrated activity against recurrent pediatric solid tumors.

KW - Angiogenesis

KW - Cyclophosphamide

KW - Topotecan

KW - Vascular targeting

UR - http://www.scopus.com/inward/record.url?scp=0842312987&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0842312987&partnerID=8YFLogxK

M3 - Article

VL - 42

SP - 93

EP - 98

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 1

ER -